Be the first to like this
European venture capital firm Sofinnova Partners has closed its sixth fund, Sofinnova Capital VI, on €260m, following what the firm describes as its most successful year.
Investors in the fund include CDC Enterprises, Industrial & Financial Investments, JP Morgan Asset Management, funds advised by Partners Group and Skandia Life Insurance Company.
Eight start-ups and spinoffs have already been invested in by Sofinnova Capital VI. These deals include Celsius, CoAxia Inc, Crescendo Biologics, DNP Green Technology Inc, Flexion Therapeutics, MD Start, Mydeco and Sagem Wireless.
Recortar slides é uma maneira fácil de colecionar informações para acessar mais tarde.